State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes

State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes

In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval...

Full description

Bibliographic Details
Main Authors: Elisa Tassinari, Linda Danielli, Andrea Marchetti, Matteo Rosellini, Costantino Ricci, Pietro Piazza, Angelo Mottaran, Riccardo Schiavina, Matteo Santoni, Veronica Mollica, Francesco Massari
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Urothelial cancer
bladder cancer
adjuvant therapy
immunotherapy
muscle-invasive bladder cancer
non-muscle invasive bladder cancer
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2440165

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2440165

Similar Items